FDA Approves Cabenuva to Treat HIV in Adolescents 12 Years of Age or Older
March 30th 2022FDA approves expanded indication for the treatment of HIV-1 in virologically suppressed adolescents 12 years of age or older, who weigh at least 35 kg, and who are on a stable antiretroviral regimen, with no history of treatment failure or known or suspected resistance to either cabotegravir or rilpivirine.
Read More